Table 3.
Initial clinical staging | Relative upstaging by mpMRI | Relative downstaging by mpMRI | mpMRI staging | |
---|---|---|---|---|
T1–T2a ((very) low-risk) | 53 (43.4%) | 67.9% | n.a. | 31 (19.4%) |
T2b-c (intermediate-risk) | 44 (36.1%) | 36.4% | 13.6% | 49 (40.6%) |
T3a-b ((very) high-risk) | 25 (20.5%) | 2.5% | 36% | 46 (37.7%) |
T stage for the patients (n = 122) was attributed to specific risk groups according to the National Comprehensive Cancer Network prostate cancer guidelines. Initial clinical staging included digital rectal examination, ultrasound-guided transrectal biopsy as well as an abdominal and pelvic contrast-enhanced CT scan.